Deric Ravsten, DO
Psychiatry · Roseburg, ORNPI 1154431542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 270 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $870 and has fallen 66.0% since, to $295 in 2025. Among psychiatry clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 270 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$902
- Johnson & Johnson$637
- Otsuka America Pharmaceutical, Inc.$554
- Sunovion Pharmaceuticals Inc.$268
- Alkermes, Inc.$264
- plus $1K from 14 others
What the payments were for
- Food & beverage$4,37691%
- Education$4309%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 46 | $1,087 |
| AbbVie(2 entities) | 53 | $902 |
| Johnson & Johnson | 49 | $637 |
| Otsuka America Pharmaceutical, Inc. | 32 | $554 |
| Sunovion Pharmaceuticals Inc. | 21 | $268 |
| Alkermes, Inc. | 14 | $264 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $183 |
| Axsome Therapeutics, Inc. | 6 | $176 |
| Vanda Pharmaceuticals Inc. | 6 | $109 |
| E.r. Squibb & Sons, L.L.C. | 3 | $84 |
| Indivior Inc. | 4 | $62 |
| Lundbeck LLC | 3 | $62 |
| Neuronetics, Inc. | 1 | $43 |
| Eisai Inc. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Merck | 1 | $11 |
How this compares
$4,806 in reported general payments places this provider in the 95th percentile of 366 psychiatry providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 30 | $91,254 |
| VraylarCariprazine Hcl | 23 | $32,943 |
| Abilify MaintenaAripiprazole | 13 | $27,284 |
| Clozapine | 63 | $13,379 |
| Olanzapine | 187 | $12,555 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $11,305 |
| Aripiprazole | 124 | $10,291 |
| Divalproex Sodium | 62 | $5,980 |
| Divalproex Sodium ErDivalproex Sodium | 98 | $5,062 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 30 | $3,871 |
| Atomoxetine Hcl | 26 | $3,731 |
| Lurasidone Hcl | 17 | $3,476 |
| Quetiapine Fumarate | 131 | $2,329 |
| Duloxetine Hcl | 100 | $2,042 |
| Ziprasidone Hcl | 32 | $2,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $637 | $91,25430 claims |
| AbbVieVraylar | $902 | $32,94323 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $554 | $27,28413 claims |
| Axsome Therapeutics, Inc.Auvelity | $176 | $11,30512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 366 psychiatry providers in Oregon.
Other psychiatry in Roseburg
- Andrew WilliamsBeaverton$84K
- Jacqueline AmatoMedford$27K
- Alisha MorelandPortland$20K
- Leigh Anne BresslerPortland$15K
- John LipkinEugene$15K
- Alfred LewyPortland$9K
- Hernan SchmidtEugene$8K
- Anca Maria BejenaruPortland$6K
- Erik VanderlipLake Oswego$6K
- Victor RichensteinEugene$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.